Jupiter Neurosciences IncJupiter Neurosciences Inc
Jupiter Neurosciences Inc

Jupiter Neurosciences Inc

JUNS
Health Care·Pharmaceuticals

Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company engaged in treating neuroinflammation with a current focus on CNS disorders and rare diseases. The firm offers JOTROL, an enhanced orally administered resveratrol formulation, designed to deliver therapeutically relevant, safe levels of resveratrol. The company was founded by Christer Rosén, Alexander Rosén, Claes Wahlestedt, Marshall Hayward, and Shaun P. Brothers in January 2016 and is headquartered in Jupiter, FL.

Florida; U.S.A
Market cap
$2.2MNo data
Revenue
$21.8K−75.8% YoY
Net income
No dataNo data
Free cash flow
$-5.4M−38.4% YoY

Market

Listed stock
JUNSPriceNasdaq
Loading…Loading…1Y

Financial performance

Revenue
$21.8K−75.8% YoY
Operating income
$-8.9M−188.2% YoY
Net income
No dataNo data
Free cash flow
$-5.4M−38.4% YoY

Revenue, profit & cash trend

Revenue
Operating income
Free cash flow
Reference
Revenue: 2021 $638K, 2022 $233.3K, 2023 $0, 2024 $90K, 2025 $21.8K. Operating income: 2021 $-3.9M, 2022 $-3.4M, 2023 $-3.9M, 2024 $-3.1M, 2025 $-8.9M. Free cash flow: 2021 $-1.7M, 2022 $-1.2M, 2023 $-481K, 2024 $-3.9M, 2025 $-5.4M. Reference line: Reference at $0.

Growth & profitability

Revenue growth
No dataNo data
Gross margin
No dataNo data
Operating margin
No dataNo data
FCF margin
No dataNo data

Earnings power over time

Operating income
Free cash flow
Operating income: 2021-12-31 $-3.9M, 2022-12-31 $-3.4M, 2023-12-31 $-3.9M, 2024-12-31 $-3.1M, 2025-12-31 $-8.9M. Free cash flow: 2021-12-31 $-1.7M, 2022-12-31 $-1.2M, 2023-12-31 $-481K, 2024-12-31 $-3.9M, 2025-12-31 $-5.4M

Growth heatmap

2022202320242025CAGR
Revenue
-63.4%
-100.0%
No data
-75.8%
No data
Gross profit
-63.4%
-100.0%
No data
-80.5%
No data
Operating income
+12.1%
-12.8%
+20.1%
-188.2%
No data
Free cash flow
+28.0%
+61.5%
-713.2%
-38.4%
No data

Earnings quality

Operating cash flow
$-5.4M−38.4% YoY
Net income
No dataNo data
Free cash flow
$-5.4M−38.4% YoY
Diluted EPS
No dataNo data

Cash conversion quality

No data

Per-share economics

Diluted EPS
Latest
No data
FCF / share
Latest
No data
Diluted shares
Latest
No data

Financial flexibility

Cash & equivalents
No dataNo data
Total debt
No dataNo data
Net debt
No dataNo data
Current ratio
No dataNo data

Cash Coverage of Debt

Cash / Total debt
No data

Returns

Return on equity
No dataNo data
Return on assets
No dataNo data
Return on invested capital
No dataNo data
Asset turnover
No dataNo data

Return on capital

No data

Valuation

Price to earnings
No dataNo data
Price to sales
No dataNo data
EV / EBITDA
No dataNo data
Free cash flow yield
No dataNo data

Valuation vs its own 5Y history

Metric
Own five-year range
Current
Own 5Y median
Position in own range
Price to earnings
No data
No data
No data
No data
Price to sales
No data
No data
No data
No data
EV / EBITDA
No data
No data
No data
No data
Free cash flow yield
No data
No data
No data
No data